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Objective: The objective of this study was to investigate the results of handmade polytetrafluoroethylene trileaf-
let conduits implanted in the pulmonary position since 1997.
Methods: One hundred thirty-nine patients underwent pulmonary reconstruction with a polytetrafluoroethylene
conduit. Conduit function was investigated by means of review of serial echocardiographic studies.
Results: Mean age and body weight were 12.7  12.0 years and 30.9  20.6 kg. Mean size of the conduit
was 21.0  3.8 mm (12–28 mm). The z score of the conduit wasþ0.5  0.8 for patients older than 15 years
(n ¼ 43),þ1.2  0.7 for patients 5 to 15 years old (n ¼ 48), andþ2.4  0.5 for patients younger than 5 years
(n ¼ 48). Conduits were used for the Ross procedure in 21 patients and for repair of complex congenital heart
disease in 118 patients. There were 3 (2.2%) in-hospital deaths and 1 late death. Four patients required
conduit explantation because of pulmonary artery distortion at a distal anastomotic site (interval, 1.2 years),
infection of the polytetrafluoroethylene valve (interval, 1.6 years), midportion angulation of the conduit
(interval, 4.9 years), and conduit compression by the ascending aorta (interval, 5.4 years). Estimated freedom
from conduit explantation was 88.0%  6.8%, and pulmonary insufficiency was less than or equal to mild in
75.0% at 10 years. All valves maintained their motion, and the mean estimated pressure gradient across the
conduit was 19.6  11.9 mm Hg at 5 years and appeared to reach a plateau thereafter. The pressure gradient
across the conduit was 14.2  8.0 mm Hg at 3 years (P ¼ .0127) and 18.1  7.5 mm Hg at 7 years
(P ¼ .0208).
Conclusions: Polytetrafluoroethylene conduits represent a valid option and reliable alternative to homograft and
xenograft implantation for pulmonary reconstruction.Earn CME credits at
http://cme.ctsnetjournals.org
Extracardiac conduits of any material used for the pulmo-
nary artery have an inherent tendency toward late failure.
Even homografts, the most widely used conduits, do not al-
ways ensure the best possible durability1,2 because calcific
fibrosis has been noted to occur, particularly in very young
patients. Furthermore, homografts are not always available.
For these reasons, xenografts or other synthetic conduits
have been used as alternatives.
Polytetrafluoroethylene (PTFE) is chemically inert, has
low friction, and possesses low tissue affinity. Therefore it
is theoretically resistant to degeneration or calcification
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valve.3 In our institute we have used Dacron conduits that in-
corporate a trileaflet PTFE valve for pulmonary reconstruc-
tion since 1997. The purpose of this study was to analyze the
results of this particular PTFE conduit.
MATERIALS AND METHODS
Construction of the Conduit
For more information on construction of the conduit, see Figures 1 to 3.
A Dacron conduit (Hemashield; Boston Scientific Corp, Natick,Mass) of an
appropriate size is provided first. Then a 0.1-mm PTFE membrane (Gore-
Tex; W. L. Gore & Associates, Inc, Newark, Del) is cut in a rectangular
shape. Six equally sized rectangular grids are drawn with a marking pen,
leaving a 1-mm margin on both sides and a 2-mm margin at the top. The
sheet is then folded, leaving the top margin. It is separated by suture lines,
using running stitches of 6-0 polypropylene sutures to create 3 pockets, and
rolled. Both sides are then sutured together to create a syringe-shaped struc-
ture with 3 separate pockets on the inside. The valve is pushed inside and
fixed onto the Dacron conduit by suturing the top and bottom ends of the
PTFE valve with running stitches of 5-0 polypropylene sutures. After fixing
the valve, the outer layer of the PTFE valve (at the midpoint of the sinus por-
tion of the valve) is sutured to the conduit to avoid free-floating material.
Commissural sutures (1 mm distant from the commissure) are finally placed
to improve valve coaptation.
Implantation of the Conduit
All patients underwent a standard first-time or redo median sternotomy.
Cardiopulmonary bypass was established with ascending aortic and bicaval
cannulations. If present, the ventricular septal defect was first closed. After
creation of the openings in the pulmonary artery and the right ventricle (left
ventricle in 11 patients with corrected transposition of the great arteries), thegery c January 2009
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DAbbreviation and Acronym
PTFE ¼ polytetrafluoroethylene
conduit was cut to the appropriate length. The distal end of the conduit was
trimmed off at approximately 0.5 to 1 cm from the distal margin of the PTFE
valve. The distal anastomosis of the conduit with the pulmonary artery was
first performedwith a running suture. The proximal endwas then trimmed to
an appropriate shape, and the proximal anastomosis with the ventricle was
performed with a running suture and reinforced with an autologous pericar-
dial strip.
Echocardiographic Measurements
We collected data regarding conduit function, including the degree of
pulmonary insufficiency and estimated pressure gradient across the conduit,
from the echocardiographic studies performed every year after conduit im-
plantation by our cardiologists. If flow velocity was clearly detected inside
the conduit, the pressure gradient was estimated by the highest maximum
flow velocity with the cursor pointed toward the direction of the conduit.
There was an average of 3.4 studies per patient, with a total of 477 studies.
Of these, 60 (12.6%) were not available for review. In some cases (n ¼ 22,
4.6% of all studies) the flow velocity was not obtained inside the conduit,
but the tricuspid regurgitation jet was identified. In that case the pressure
gradient was estimated by using the following formula: [(Predicted right
ventricular pressure from the maximal flow velocity of tricuspid regurgita-
tion flow)20]. This formula assumes that the right atrial pressure was 10
mm Hg and the systolic pulmonary pressure was 30 mm Hg. Pulmonary in-
sufficiency was graded as none to trivial, mild (regurgitation flow confined
within the lumen of the conduit, central deficiency during closure of leaflets
not visible), moderate (regurgitation flow extending beyond the proximal
conduit–right ventricular anastomosis), and severe (massive regurgitation
flow through a visible central deficiency at the time of diastole with
restricted or absent leaflet motion).
Data Analysis
StatView statistical software for Windows (version 5.0; SAS Institute,
Inc, Cary, NC) was used for data analysis. Values were expressed as means
 standard deviation or median. Time-dependent outcomes were assessed
with Kaplan–Meir analysis, with the log-rank test used to evaluate group
differences. All probability values were 2-tailed. Locally weighted polyno-
mial (Lowess) regression line was drawn based on a weighted linear least
squares regression over the span of values of the y-axis scattergram criterion
variable.
The study was approved by the Institutional ReviewBoard of Sakakibara
Heart Institute, and the procedures were in accordance with institutional
guidelines for protection of patient confidentiality. The need for patient con-
sent was waived.
RESULTS
Basic Demographic Information
One hundred thirty-nine patients underwent pulmonary
reconstruction with the PTFE conduit. Follow-up was com-
plete in 127 (91.4%) of 139 patients as of November 2007.
The mean follow-up period was 2.7 2.4 years. There were
55 female patients. Mean age and body weight at the time of
the operation were 12.7  12.0 years (0.07–62.5 years) and
30.9  20.6 kg (3.4–101 kg), respectively.The Journal of Thoracic and CAnatomic diagnosis and surgical status are listed in Table 1.
Conduits were placed from the left ventricle to the pulmo-
nary artery in 11 patients (conventional Rastelli procedure)
and from the right ventricle to the pulmonary artery in 4
(double-switch operation) for patients with corrected trans-
position of the great arteries, ventricular septal defect, and
left ventricular outflow tract obstruction. Four patients
with ventricular septal defect, left ventricular outflow tract
obstruction, and well-developed ventricles underwent
conduit replacement after former Norwood-type arch repair
and biventricular repair.
Preexisting cardiac problems included severe hypoplasia
or discontinuous branch pulmonary arteries in 8 patients, se-
vere hypoplasia or complete absence of the right or left pul-
monary artery in 5 patients, complete atrioventricular block
requiring pacemaker implantation in 3 patients, residual ven-
tricular septal defect after previous repair in 2 patients, se-
vere tricuspid regurgitation in 2 patients, and ventricular
tachyarrhythmia in 1 patient.
FIGURE 1. Schematic drawings of the steps of conduit construction. The
width of each grid on the polytetrafluoroethylene sheet (a) is determined as
follows: [(Diameter of the Dacron conduit) 3 1.05] in millimeters. The
height of each grid (b) is determined as follows: (a 3 0.8) in millimeters.
The created polytetrafluoroethylene valve is fixed inside the Dacron conduit
by suturing the top (1) and bottom (2) ends. After fixing the valve, each
valve is sutured together at the point of a 1-mm distance from each commis-
sure (3) to improve valve coaptation. The outer layer of the polytetrafluoro-
ethylene valve is then sutured at the midpoint (4) to the conduit to avoid free
floating.ardiovascular Surgery c Volume 137, Number 1 125
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DFIGURE 2. Grids are drawn on the polytetrafluoroethylene sheet (A). The folded sheet is separated by suture lines to create 3 pockets (B). Both sides are then
sutured together (C) to create a syringe-shaped trileaflet valve (D).First-time complete repair (Rastelli procedure) was
performed in 58 (41.7%) patients, and a nonreoperative
Ross procedure was performed in 19 (13.7%) patients.
Forty-one (29.5%) patients underwent conduit replacement
after previous Rastelli or Ross procedures, and 21 (15.1%)
patients underwent conduit placement after previous
intracardiac repair by using right ventricular outflow recon-
struction.126 The Journal of Thoracic and Cardiovascular SuOne patient with complete transposition of the great ar-
teries, ventricular septal defect, and left ventricular outflow
tract obstruction had undergone a palliative Senning opera-
tion previously. This patient underwent takedown of the
Senning baffle, closure of the ventricular septal defect, and
morphologic left ventricle–pulmonary artery conduit place-
ment. Other concomitant procedures included tricuspid
repair or replacement in 11 patients, extended pulmonaryFIGURE 3. The valve is pushed inside (A) and fixed onto the Dacron conduit by suturing the top and bottom ends of the polytetrafluoroethylene valve (B).
Commissural sutures are placed at the point of a 1-mm distance from the commissure (arrow in C). The outer layer of the polytetrafluoroethylene valve is
sutured to the conduit at the midpoint of the sinus (arrow in D).rgery c January 2009
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Darterial plasty in 7 patients, mitral valve plasty or replace-
ment in 3 patients, aortic valve plasty or replacement in 3
patients, resection of subaortic stenosis in 2 patients, pulmo-
nary unifocalization in 2 patients, the Senning procedure
(double switch) in 2 patients, and pacemaker implantation
in 1 patient.
The size of the conduit used was 12 mm in 2 patients, 14
mm in 4 patients, 16 mm in 20 patients, 18 mm in 22 pa-
tients, 20 mm in 16 patients, 22 mm in 26 patients, 24 mm
in 24 patients, 26 mm in 24 patients, and 28 mm in 1 patient,
with a mean conduit size of 21.0 3.8 mm (12–28mm). The
z score of the conduit wasþ0.5  0.8 for patients older than
15 years (n ¼ 43),þ1.2  0.7 for those 5 to 15 years of age
(n ¼ 48), andþ2.4  0.5 for patients younger than 5 years
(n ¼ 48).
Operative and Late Mortality
There were 3 (2.2%) in-hospital deaths and 1 late death.
The first patient, who underwent the Ross procedure for
congenital aortic stenosis, had severe left ventricular dys-
function after the operation. Despite maximal effort to resus-
citate the ventricle, the patient died on the first day after the
operation. This death was thought to be attributable to the
imperfect myocardial protection in the setting of severe
left ventricular hypertrophy.
The second patient underwent an operation for repair of
ventricular septal defect and pulmonary atresia. After wean-
ing from cardiopulmonary bypass, multiple communica-
tions between both ventricles were found. Unsuccessful
attempts were made to close these additional defects. The
patient had severe cardiac dysfunction and died on the day
after the operation.
The third patient, with a ventricular septal defect and pul-
monary atresia, underwent an uneventful operation, and the
postoperative course in the intensive care unit was also un-
eventful. After transfer to the ward, the patient had sudden
TABLE 1. Anatomic diagnosis and operative status
Anatomic diagnosis
First-time
operation
S/P
ECR
S/P
RVOTR Total
VSD with pulmonary atresia 30 14 1 45
TOF/DORVþPS 10 8 15 33
AS/AR/ASþAR (Ross procedure) 19 2 0 21
Corrected TGA (LV–PA conduit) 9 2 0 11
Corrected TGA (RV–PA conduit) 2 2 0 4
TGAþLVOTO 3 4 0 7
Truncus arteriosus 2 5 0 7
PS/PA without VSD 2 0 5 7
VSDþLVOTO 0 4 0 4
S/P ECR, Status after extracardiac conduit repair; S/P RVOTR, status after right ven-
tricular outflow tract obstruction; VSD, ventricular septal defect; TOF, Tetralogy of
Fallot; DORV, double-outlet right ventricle; PS, pulmonary stenosis; AS, aortic steno-
sis; AR, aortic regurgitation; TGA, transposition of the great arteries; LV–PA, left ven-
tricle–pulmonary artery; RV–PA, right ventricle–pulmonary artery; LVOTO, left
ventricular outflow tract obstruction; PA, pulmonary atresia.The Journal of Thoracic and Crespiratory arrest followed by cardiac arrest. Despite resusci-
tation, the patient died on day 2 from the operation. The
cause of death was not identified.
The fourth patient, with a diagnosis of ventricular septal
defect and pulmonary atresia, had undergone bilateral
systemic–pulmonary artery shunts before complete repair.
The distortion of both pulmonary arterial branches at the
site of shunt anastomosis was not successfully relieved
and resulted in a high right ventricular pressure with severe
dysfunction. This patient died of heart failure at 9.5 months.
Other Postoperative Complications
One patient, who underwent the Ross operation, had sud-
den cardiac arrest on the day of the operation, presumably
because of imperfect myocardial protection during the oper-
ation. The patient subsequently recovered, and the remain-
der of the hospital course was uneventful.
Other postoperative complications included prolonged
pleural effusion requiring chest tube placement for 7 days
or longer in 5 patients, atrial fibrillation requiring cardiover-
sion in 2 patients, sternotomy wound infection in 2 patients,
phrenic nerve paralysis in 2 patients, protein losing enterop-
athy (present before the operation) in 1 patient, ventricular
tachyarrhythmia requiring cardioverter defibrillator implan-
tation in 1 patient, reoperation for bleeding in 1 patient, and
complete atrioventricular block requiring pacemaker inser-
tion in 1 patient.
Conduit Explantation
Thirty-one patients underwent a follow-up catheterization
after the operation. Indications included suspected pulmo-
nary stenosis in 6 patients, potential intervention for residual
branch pulmonary stenosis in 6 patients (for whom angio-
plasty was done in 2 patients), aortic regurgitation in 3 pa-
tients, and decreased left ventricular function in 2 patients.
In the other 14 patients, catheterization was performed to
generally assess cardiac performance with no suspected ab-
normality. Among them, conduit stenosis requiring replace-
ment was found in 4 patients.
The first patient had pulmonary artery distortion at the
distal conduit–pulmonary artery anastomosis. This patient
also had a residual ventricular septal defect and a patent
systemic–pulmonary artery shunt. This patient underwent
closures of the residual ventricular septal defect and sys-
temic–pulmonary artery shunt and replacement of the pul-
monary conduit at 1.2 years.
The second patient had also pulmonary artery distortion at
the distal conduit–pulmonary artery anastomotic site, as well
as a midportion angulation requiring conduit replacement at
4.9 years.
The third patient had pseudoaneurysm at the proximal su-
ture line of the autograft after a Ross procedure. This caused
an extrinsic compression of the pulmonary conduit andardiovascular Surgery c Volume 137, Number 1 127
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Dstenosis. The patient required repair of the pseudoaneurysm
and pulmonary conduit replacement at 5.4 years.
The fourth patient, with a ventricular septal defect and
pulmonary atresia, underwent conduit replacement with
a PTFE conduit. The patient had previously experienced ep-
isodes of ventricular tachycardia, which exacerbated after
the operation. The patient received implantable cardioverter
defibrillator, resulting in the lead infection. After removal of
the defibrillator, the patient manifested persistent staphylo-
coccal bacteremia, resulting in infection of the PTFE valve.
The patient eventually required replacement of this conduit
at 1.6 years.
Estimated freedom from conduit replacement was 97.8%
 1.6% at 3 years, 93.5% 4.4% at 5 years, and 88.0%
6.8% at 10 years.
Other Reoperations not Requiring Conduit
Explantation
Two patients with ventricular septal defect and pulmonary
atresia required aortic valve replacement for progressive aor-
tic valve insufficiency at 1.9 and 7.6 years, respectively. The
third patient underwent one and a half ventricle repair for pul-
monary atresia with intact ventricular septum. The patient had
right heart failure because of the hypoplastic right ventricle
and required creation of the atrial septal defect at 4.6 months.
The fourth patient, with aortic atresia and a ventricular septal
defect, had ascending aortic stenosis and underwent aorto-
plasty at 1.5 months. Pulmonary conduits were considered
to be intact in these patients and were not replaced.
Conduit Function on Echocardiographic Analysis
The mean estimated pressure gradient across the conduit
was 9.4  6.5 mm Hg immediately after the operation,
FIGURE 4. Scatterplots of estimated pressure gradient across the conduit
for the polytetrafluoroethylene valved conduit as a function of time interval
after the procedure. The markers indicate the mean pressure gradient, and
bars indicate the standard deviations. The solid lines were derived by the
locally weighted polynomial (Lowess) regression of the data. Numbers in
parentheses indicate patients at risk.128 The Journal of Thoracic and Cardiovascular Sur14.2  8.0 mm Hg at 3 years, and 19.6  11.9 mm Hg at
5 years and appeared to reach a plateau thereafter (Figure 4).
When divided by the size of the conduit, the mean pressure
gradient of a conduit of greater than 20mm reached a plateau
at 5 years and remained within 20 mmHg until 10 years. The
mean pressure gradient, however, reached 20 mm Hg at
4 years for a conduit size of 16 to 18 mm and at 2 years
for 12 to 14 mm (Figure 5). When analyzed by the different
procedures performed, conduits used in the Ross procedure,
in right ventricle–pulmonary artery reconstruction in the
heart with normally related great arterial relationship, and
for left ventricle–pulmonary artery reconstruction exhibited
similar gradients. On the contrary, the mean pressure gradi-
ent increased exponentially in the right ventricle–pulmonary
artery conduit in hearts with transposition of the great ar-
teries (Figure 6). All valves maintained their motion, and
pulmonary insufficiency was less than or equal to mild in
75.0% at 10 years (Figure 7).
Histological Findings on the Explanted Specimen
For more information on histologic findings on the
explanted specimen, see Figure 8.
In the PTFE valve specimen of the explanted conduit at
5.4 years, the surface of the valve was smooth, and the valve
itself was pliable. On microscopic evaluation, there was no
structural deterioration of the PTFEmembrane, cellular infil-
tration, or calcification noted.
DISCUSSION
The extracardiac conduit placed in the pulmonary position
is almost always subject to functional deterioration. Even
FIGURE 5. Scatterplots of estimated pressure gradient across the conduit
as a function of time interval after the procedure. The markers indicate the
mean pressure gradient for the conduit sized greater than 20 mm (solid cir-
cles), 16 or 18 mm (open circles), and 12 or 14 mm (solid squares). The
solid lines were derived by the locally weighted polynomial (Lowess) re-
gression of the data. Numbers in parentheses indicate patients at risk for
conduit size 12/14 mm (top row), 16/18 mm (middle row), and greater
than 20 mm (bottom row).gery c January 2009
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construction, are not exempt from failure, and replacement
might become mandatory at some point in the patient’s life.
In general, results of homografts used for pulmonary re-
construction in the Ross procedure have been excellent,
with reported freedom from reintervention of greater than
90% at 5 years.4 In the non-Ross population, however,
some report poor performance of homografts.1 According
to another report, somatic outgrowth is seldom a primary
FIGURE 6. Scatterplots of estimated pressure gradient across the conduit
as a function of time interval after the procedure. The markers indicate the
mean pressure gradient for the conduit placed from the right ventricle to the
pulmonary artery in patients having transposition of the great arteries (RV-
PA TGA, open squares), from the right ventricle to the pulmonary artery in
patients undergoing the Ross procedure (open circles), from the right ven-
tricle to the pulmonary artery in patients with normally related great arteries
(RV-PA NGA, solid squares), and from the left ventricle to the pulmonary
artery in patients having corrected transposition of the great arteries (LV-
PA, solid circles). The solid lineswere derived by the locally weighted poly-
nomial (Lowess) regression of the data. Numbers in parentheses indicate
patients at risk for RV-PA NGA, Ross, RV-PA TGA, and LV-PA (top to
bottom rows).
FIGURE 7. Progression of pulmonary regurgitation until 10 years after the
operation. Numbers in parentheses indicate patients at risk.The Journal of Thoracic and Creason for homograft conduit replacement, but rather con-
duit obstruction with thickening and shrinkage at the annular
area is more frequently responsible for failure.5 Especially
when aortic homografts are used in young patients, acceler-
ated aortic homograft fibrocalcification can occur. Blood
group incompatibility between receiver and homograft
donor also seems to play an important role in the develop-
ment of accelerated fibrocalcifications in cryopreserved
homografts.6 Some even report the inferior longevity of
homografts when compared with porcine valved Dacron
conduits.1
Commercially available glutaraldehyde-preserved xeno-
graft pericardial valved conduits (Hancock valved conduit,
Medtronic, Minneapolis, Minn; Carpentier–Edwards valved
conduit, Edwards Lifesciences, Irvine, Calif) have been
widely used since the 1970s. These conduits are known to
be associated with a disturbing incidence of late failure,7,8
with 1 report showing a total incidence of 30% xenograft
conduit failure in a 6-year follow-up.9More recently, a xeno-
graft valved conduit using a decalcification process to miti-
gate tissue degeneration and calcification associated with
glutaraldehyde (Shelhigh conduit; Shelhigh, Inc, Union,
FIGURE 8. Polytetrafluoroethylene valve specimens explanted at 5.4
years after implantation (top). Microscopic image of the same specimen
stainedwithMilligan’s trichrome stain (bottom). (Original magnitude 203.)ardiovascular Surgery c Volume 137, Number 1 129
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DNJ) has become commercially available.10 This conduit,
however, was also associated with a high incidence of early
failure caused by pseudointimal peel formation that led to
multilevel conduit stenosis.11,12
Glutaraldehyde-preserved bovine jugular vein (Contegra;
Medtronic, Inc) conduits are now considered a sound alter-
native to homografts for pulmonary reconstruction, with re-
ported freedom from graft dysfunction and reoperation of
greater than 90% at 7 years postoperatively.13 This particu-
lar conduit might be especially useful for right ventricular
outflow tract reconstruction in neonates and infants.14 How-
ever, distal conduit stenosis is frequently seen among youn-
ger patients and patients with small pulmonary arteries.
Also, significant graft dilatation was observed in patients
with pulmonary artery branch obstruction or pulmonary hy-
pertension.15 Some advocate cautious use of these conduits
in patients with predicted high right ventricular/left ventric-
ular pressure ratios.16
PTFE has very low tissue affinity. Because of this prop-
erty, cellular or fibrinous deposition is unlikely, and for these
reasons, it is the most reliable material for small-caliber vas-
cular grafts.17 Moreover, because of its chemical inertness,
tissue degeneration or destruction is unlikely or very slow
to progress. These properties make PTFE an ideal biomate-
rial for valve replacement, especially in the pulmonary posi-
tion. Brown and colleagues3 reported excellent results with
right ventricular outflow tract reconstruction by using
a PTFE monocusp valve. They did not witness significant
calcification or pulmonary embolization, and the only antith-
rombotic agent used was low-dose aspirin. According to our
results, PTFE conduits have comparable longevity when
used in the pulmonary position when compared with the re-
ported results of blood-compatible homografts or Contegra
conduits, particularly with respect to larger-sized conduits.
In some countries, such as Japan, the access to homografts
or xenograft products of Western countries (ie, Contegra)
is limited. The PTFE conduit is inexpensive and always
available and therefore could be the conduit of choice in
these circumstances. Even in Western countries, homografts
are not always available in an ideal size. In this context the
PTFE conduit might be a good choice, especially if the pa-
tient has a high pulmonary artery pressure, for which the
Contegra conduit might not be an optimal choice. The fol-
low-up of smaller-sized PTFE conduits is currently limited,
with the longest observation period of the smallest size
(12 mm) being only 1.5 years. Longer follow-up is required
to assess the performance of the smaller-sized PTFE conduit
to extrapolate meaningful comparative data with homografts
and Contegra conduits.
Another group reported the results of handmade trileaflet
conduits made of heterologous pericardium or PTFE for
right ventricular outflow tract reconstruction.18 The reported
freedom from important pulmonary valve regurgitation was
68.3%  3.7% at 5 years, 33.0%  4.5% at 10 years, and130 The Journal of Thoracic and Cardiovascular Su21.6%  4.9% at 15 years. Conduits included whole heter-
ologous pericardial trileaflet conduits in 169 patients and bo-
vine pericardial conduits containing PTFE leaflets in 26
patients.Whole PTFE trileaflet rolls were used in only 21 pa-
tients. It is important to note that when materials with differ-
ent tissue affinities are sutured together, tissue pannus might
form at the junction. An example of this is the intimal peel
formation leading to valve dysfunction observed in xeno-
graft valved Dacron conduits.19 Because PTFE has very
low tissue affinity, intimal or pseudointimal ingrowths
from the adjacent tissue can easily be peeled off and form
a pannus. If the PTFE valve is directly sutured to the heter-
ogenous substance, such as xenograft pericardium, a similar
phenomenon can occur, which can lead to valve dysfunc-
tion. Therefore it is especially important that the outer wall
of the PTFE valve leaflet (sinus portion) should be a PTFE
substance. To achieve this, one can suture the PTFE mem-
brane directly to the PTFE conduit.20 It is also possible to
fold the PTFE membrane before suturing it inside the outer
conduit, as we presently do. We prefer to use a Hemashield
conduit (St JudeMedical, St Paul, Minn) for several reasons,
including the ease of hemostasis, the stiffness of the conduit
(making itself resistant to external compression), and its in-
herent structure, which is resistant to angulation. It should be
also noted that the PTFE membrane is folded, leaving a few
millimeters excess at the top end, which gives some space
between the suture line with the Dacron conduit and the si-
nus of each valve. We believe the pannus, even if formed,
can be peeled off before it intrudes into the sinus, preserving
the function of the valve.
Our results confirmed that the long-term results of the
Rastelli operation for management of patients with transpo-
sition of the great arteries, ventricular septal defect, and
pulmonary stenosis are still somewhat suboptimal. Aortic
translocation and biventricular outflow tract reconstruction
might be an alternative for the management of these patients
to reduce postoperative right ventricular outflow tract
failure.21
Conduits are routinely oversized to account for somatic
growth in children requiring right ventricle–pulmonary ar-
tery continuity. However, there is an increasing awareness
of the fact that excessive oversizing of the conduit placed
in the pulmonary position results in decreased longevity in
children.22 Pulmonary conduit durability and hemodynamic
function in patients undergoing initial conduit insertion at
less than 2 years of age can be improved by using pulmonary
conduits with z scores betweenþ1 andþ3.23 The target z
score of the conduit in our cohort wasþ2 in the small chil-
dren aged less than 5 years,þ1 for those aged 5 to 15 years,
and the normal size for those aged 15 years or older.
Thedistal endof the conduitwas cut off, leavingonly a 1/2 - to
1-cmmargin from the top end of the PTFE valve. Because the
conduit usually forms an acute-angled curve after arising
from the ventricle to be oriented toward the pulmonaryrgery c January 2009
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Dartery, positioning of the valve renders itself to distortion.
This technique allows the valve to be positioned in the
straight portion of the conduit, leading to the maintenance
of its intact shape.
The limitations to this study include the retrospective na-
ture of the study design and that echocardiograms had been
obtained by one of our 7 attending cardiologists. Therefore
each study might be highly subjective to the bias of each
investigator.
In summary, PTFE valved conduits showed acceptable
functional durability and maintained valve motion for up
to 10 years in all patients in this series. As is shown in this
study, late valve fixation in the semiopen position did not
occur. Because of this, development of the pressure gradient
reached a plateau in conduits with a size of greater than
20 mm, and there was no reoperation because of structural
deterioration during this time period. In our opinion PTFE
conduits represent a valid option and a reliable alternative
to homograft and xenograft implantation for pulmonary
reconstruction.
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